BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 17846002)

  • 1. [Genetics and angiogenesis: the example of von Hippel-Lindau disease].
    Richard S; Ladroue C; Gad S; Giraud S; Gardie B;
    Bull Cancer; 2007 Jul; 94 Spec No():S170-9. PubMed ID: 17846002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Von Hippel-Lindau: how a rare disease illuminates cancer biology.
    Richard S; Gardie B; Couvé S; Gad S
    Semin Cancer Biol; 2013 Feb; 23(1):26-37. PubMed ID: 22659535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Von Hippel-Lindau disease and central nervous system hemangioblastoma. Progress in genetics and clinical management].
    Richard S; Martin S; David P; Decq P
    Neurochirurgie; 1998 Nov; 44(4):258-66. PubMed ID: 9864697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. von Hippel-Lindau disease.
    Couch V; Lindor NM; Karnes PS; Michels VV
    Mayo Clin Proc; 2000 Mar; 75(3):265-72. PubMed ID: 10725953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Von Hippel-Lindau disease: recent advances in genetics and clinical management].
    Richard S; Parker F; Aghakhani N; Allegre G; Portier F; David P; Marsot-Dupuch K
    J Neuroradiol; 2005 Jun; 32(3):157-67. PubMed ID: 16134297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. von Hippel-Lindau syndrome.
    Chou A; Toon C; Pickett J; Gill AJ
    Front Horm Res; 2013; 41():30-49. PubMed ID: 23652669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. von Hippel-Lindau disease: a clinical and scientific review.
    Maher ER; Neumann HP; Richard S
    Eur J Hum Genet; 2011 Jun; 19(6):617-23. PubMed ID: 21386872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Von Hippel-Lindau disease].
    Takahashi K; Iida K; Chihara K
    Nihon Rinsho; 2006 Sep; Suppl 3():351-4. PubMed ID: 17022562
    [No Abstract]   [Full Text] [Related]  

  • 9. [Von Hippel-Lindau disease: recent genetic progress and patient management. Francophone Study Group of von Hippel-Lindau Disease (GEFVH)].
    Richard S; Giraud S; Beroud C; Caron J; Penfornis F; Baudin E; Niccoli-Sire P; Murat A; Schlumberger M; Plouin PF; Conte-Devolx B
    Ann Endocrinol (Paris); 1998; 59(6):452-8. PubMed ID: 10189987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of molecular genetic analysis of the VHL gene in patients with haemangioblastomas of the central nervous system.
    Gläsker S; Bender BU; Apel TW; Natt E; van Velthoven V; Scheremet R; Zentner J; Neumann HP
    J Neurol Neurosurg Psychiatry; 1999 Dec; 67(6):758-62. PubMed ID: 10567493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Von Hippel-Lindau disease: molecular pathological basis, clinical criteria, genetic testing, clinical features of tumors and treatment.
    Shuin T; Yamasaki I; Tamura K; Okuda H; Furihata M; Ashida S
    Jpn J Clin Oncol; 2006 Jun; 36(6):337-43. PubMed ID: 16818478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing.
    Kaelin WG
    Cold Spring Harb Symp Quant Biol; 2005; 70():159-66. PubMed ID: 16869749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Von Hippel-Lindau disease: a single gene, several hereditary tumors.
    Crespigio J; Berbel LCL; Dias MA; Berbel RF; Pereira SS; Pignatelli D; Mazzuco TL
    J Endocrinol Invest; 2018 Jan; 41(1):21-31. PubMed ID: 28589383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of VHL gene mutation in human cancer.
    Kim WY; Kaelin WG
    J Clin Oncol; 2004 Dec; 22(24):4991-5004. PubMed ID: 15611513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. De novo VHL germline mutation detected in a patient with mild clinical phenotype of von Hippel-Lindau disease.
    Ding X; Zhang C; Frerich JM; Germanwala A; Yang C; Lonser RR; Mao Y; Zhuang Z; Zhang M
    J Neurosurg; 2014 Aug; 121(2):384-386. PubMed ID: 24678776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The von Hippel-Lindau tumor suppressor gene. A rare and intriguing disease opening new insight into basic mechanisms of carcinogenesis.
    Decker HJ; Weidt EJ; Brieger J
    Cancer Genet Cytogenet; 1997 Jan; 93(1):74-83. PubMed ID: 9062583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocrine manifestations of von Hippel-Lindau disease.
    Cassol C; Mete O
    Arch Pathol Lab Med; 2015 Feb; 139(2):263-8. PubMed ID: 25611110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel missense mutation (N78D) in a family with von Hippel-Lindau disease with central nervous system haemangioblastomas, pancreatic and renal cysts.
    Cingoz S; van der Luijt RB; Kurt E; Apaydin M; Akkol I; Ozgen MH
    Fam Cancer; 2013 Mar; 12(1):111-7. PubMed ID: 23224817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.